BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1442 related articles for article (PubMed ID: 29609897)

  • 1. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLUT1 expression in high-risk prostate cancer: correlation with
    Meziou S; Ringuette Goulet C; Hovington H; Lefebvre V; Lavallée É; Bergeron M; Brisson H; Champagne A; Neveu B; Lacombe D; Beauregard JM; Buteau FA; Riopel J; Pouliot F
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):441-448. PubMed ID: 31932660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.
    Beauregard JM; Blouin AC; Fradet V; Caron A; Fradet Y; Lemay C; Lacombe L; Dujardin T; Tiguert R; Rimac G; Bouchard F; Pouliot F
    Cancer Imaging; 2015 Mar; 15(1):2. PubMed ID: 25889163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
    Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
    Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
    Mazzone E; Gandaglia G; Robesti D; Rajwa P; Gomez Rivas J; Ibáñez L; Soeterik TFW; Bianchi L; Afferi L; Kesch C; Darr C; Guo H; Zhuang J; Zattoni F; Fendler WP; Amparore D; Huebner NA; Giesen A; Joniau S; Schiavina R; Brunocilla E; Mattei A; Dal Moro F; Moreno Sierra J; Porpiglia F; Picchio M; Chiti A; van den Bergh R; Shariat SF; Montorsi F; Briganti A
    Eur Urol Oncol; 2024 Apr; 7(2):231-240. PubMed ID: 37689506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
    Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of
    Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
    Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of [
    Kim J; Lee S; Kim D; Kim HJ; Oh KT; Kim SJ; Choi YD; Giesel FL; Kopka K; Hoepping A; Lee M; Yun M
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1763-1772. PubMed ID: 38200396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
    Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
    BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Value of
    Voskuilen CS; Schweitzer D; Jensen JB; Nielsen AM; Joniau S; Muilwijk T; Necchi A; Azizi M; Spiess PE; Briganti A; Bandini M; Goffin K; Bouchelouche K; van Werkhoven E; Shariat SF; Xylinas E; Azawi NH; Ku JH; Foerster B; van Rhijn BWG; Vegt E; Hendricksen K
    Eur Urol Oncol; 2020 Feb; 3(1):73-79. PubMed ID: 31591037
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):477-482. PubMed ID: 32696091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of primary tumor (18)F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis.
    Jung NY; Kim SH; Kang BJ; Park SY; Chung MH
    Breast Cancer; 2016 Sep; 23(5):712-7. PubMed ID: 26219608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy.
    Gultekin MH; Demirci E; Turegun FA; Kabasakal L; Sahin OE; Ocak M; Onal B; Erozenci A
    Urol J; 2020 Dec; 18(1):58-65. PubMed ID: 33349912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
    Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
    Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of
    Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
    Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.